Skip to content

Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry

Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON28193
Enrollment
500
Registered
2019-07-11
Start date
2019-07-03
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

follicular lymphoma

Interventions

None listed

Sponsors

EHA Lymphoma group
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy, All stages at the time of relapse, Histological grade 1-3a at the time of initial diagnosis, Age over 18 years, Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested, Diagnostic material available for review, Written informed consent.

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

MeasureTime frame
Rate of Progression of disease within 24 months from start of second line treatment (second POD24)

Secondary

MeasureTime frame
Overall Survival (OS), Progression-free survival after second line therapy (second PFS), Complete response rate at 30 months (CR30) from start of second line treatment (second CR30)

Contacts

Public ContactSanne Tonino

AUMC

S.h.tonino@amsterdamumc.nl0031207328135

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)